A Pioneering Treatment Journey for Extensive-Stage SCLC
Explore how a 50-year-old extensive-stage SCLC patient achieved remarkable tumor control through a strategic blend of chemotherapy, radiotherapy, targeted therapy with anlotinib, and combination immunotherapy with durvalumab.
A Pioneering Treatment Journey for Extensive-Stage SCLC Read More »